Nicotinamide treatment
Phase 3Small molecule
Nicotinamide treatment is one of 65 small molecule programs targeting Septic Shock. It is currently in Phase 3.
2
Indications
3
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
72 competitors in Septic Shock
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Glypressin
MMallinckrodt
Approved
Pitressin
AAultman Health Foundation
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Zocor
OOrganon and Co
Approved
Florinef
Jazz PharmaceuticalsPhase 3
Methylthioninium Chloride
PProvepharm SAS
Phase 3
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapiblyk
AAultman Health Foundation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Septic Shock1 trial
Does High-dose Vitamin B3 Supplementation Prevent Major Adverse Kidney Events During Septic Shock?
Active, not recruiting·—·Phase 3·NCT04589546·310 enrolled
Acute Kidney Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nicotinamide treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details